Fischer Medical Ventures Ltd (FMVL) announced that its portfolio company, Nanomedic Technologies Ltd, has achieved a key regulatory breakthrough with the registration of its SpinCare® wound care device with the UK’s National Health Service (NHS), marking a major milestone in its global expansion plans.
The NHS registration allows Nanomedic to enter one of the world’s largest healthcare systems, strengthening its commercial footprint across 34 countries in Europe, South America, and Asia. The company has already begun collaborating with one of London’s largest hospitals to initiate deployment.
Nanomedic is also preparing for a large-scale launch in India, where it has completed documentation for registration of SpinCare® and obtained a Central Drug Standard Control Organization (CDSCO) licence for imports meant for clinical investigations and demonstrations. The MD-15 commercial import licence application is currently pending approval.
As part of its Indian market strategy, the company has engaged with leading hospitals specializing in burn and chronic wound management and has started non-commercial clinical trials in collaboration with select government institutions. The firm believes its portable electrospinning-based wound dressing technology could help optimize treatment protocols, accelerate healing, and improve patient outcomes nationwide.
Nanomedic also continues to advance regulatory progress in other regions, completing Phase One of its MDR/MDD audit for CE certification renewal, with Phase Two scheduled by mid-October 2025. The company’s new VP of Clinical and North American Regulatory Affairs—an expert in FDA filings—is leading preparations for an upcoming US FDA submission later this year.
Clinical studies have reinforced SpinCare®’s efficacy, demonstrating pain relief, faster epithelialization, and reduced hospitalizations, according to peer-reviewed publications and trials conducted by Stanford University and others.
Commenting on the progress, Ravindran Govindan, Chairman and Managing Director of Fischer Medical Ventures, said, “These milestones at Nanomedic are a clear validation of our investment strategy and the transformative potential of their SpinCare® technology. The NHS registration solidifies a major European market, while the proactive steps in India demonstrate a sharp focus on impactful, localized market strategy.”
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
